Reuters logo
Hospira must pay Amgen $70 million in biosimilar patent case - jury
September 25, 2017 / 8:14 PM / 2 months ago

Hospira must pay Amgen $70 million in biosimilar patent case - jury

A federal jury has awarded Amgen Inc $70 million after finding that Hospira’s production of a biosimilar version infringed Amgen’s patent covering its anemia drug Epogen.

The verdict by a federal jury in Wilmington, Delaware, on Friday came in what Amgen has said was one of the first patent lawsuits to be filed in the wake of the 2010 Biologics Price Competition and Innovation Act.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2xsrg2V

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below